期刊
DRUG DISCOVERY TODAY
卷 22, 期 1, 页码 186-193出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2016.08.006
关键词
-
资金
- American Heart Association [16GRNT30950010]
- National Institutes of Health COBRE grant [P20GM104936]
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104936] Funding Source: NIH RePORTER
Macrophages are a heterogeneous population of phagocytic cells present in all tissues. Recently, several drugs that target the epigenetic machinery have emerged as attractive molecules for treating infection and inflammation by modulating macrophages. Treatment of lipopolysaccharide (LPS)-challenged macrophages with epigenetic modifiers leads to phenotype switching. This could provide stimulatory/destructive (M1) or suppressive/protective (M2) therapeutic strategies, which are crucial in the cytokine milieu in which the macrophages reside. In this review, we provide an overview of macrophage functional diversity during various diseases, including infection, as well as the current status in the development and clinical utility of epigenetic modifiers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据